CARA THERAPEUTICS, INC.

(CARA)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
9.390 USD   +2.96%
06/07CARA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/06Amarin Names Tom Reilly Finance Chief
MT
06/06Cara Therapeutics CFO Thomas Reilly Resigns
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cara Therapeutics' Korsuva Injection Receives TDAPA Reimbursement

12/20/2021 | 08:35am EDT


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
CARA THERAPEUTICS, INC. 2.96% 9.39 Delayed Quote.-22.91%
VIFOR PHARMA AG 0.15% 171.95 Delayed Quote.5.98%
All news about CARA THERAPEUTICS, INC.
06/07CARA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/06Amarin Names Tom Reilly Finance Chief
MT
06/06Cara Therapeutics CFO Thomas Reilly Resigns
MT
06/03CARA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/03Cara Therapeutics, Inc. Announces Resignation of Thomas Reilly as Chief Financial Offic..
CI
05/17Cara Therapeutics to Present at Upcoming Investor Conferences
GL
05/10TRANSCRIPT : Cara Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conferenc..
CI
05/09TRANSCRIPT : Cara Therapeutics, Inc., Q1 2022 Earnings Call, May 09, 2022
CI
05/09CARA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
05/09CARA : Q1 Earnings Snapshot
AQ
More news
Analyst Recommendations on CARA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 75,3 M - -
Net income 2022 -69,1 M - -
Net cash 2022 190 M - -
P/E ratio 2022 -7,34x
Yield 2022 -
Capitalization 503 M 503 M -
EV / Sales 2022 4,16x
EV / Sales 2023 2,05x
Nbr of Employees 84
Free-Float 83,7%
Chart CARA THERAPEUTICS, INC.
Duration : Period :
Cara Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 9,39 $
Average target price 24,25 $
Spread / Average Target 158%
EPS Revisions
Managers and Directors
Christopher Posner President, Chief Executive Officer & Director
Richard Makara VP, Chief Financial & Accounting Officer
Frèdèrique Menzaghi Chief Scientific Officer, Senior VP-R&D
Joana Goncalves Chief Medical Officer
Scott M. Terrillion Secretary & Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
CARA THERAPEUTICS, INC.-22.91%503
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-13.42%44 742
BIONTECH SE-48.01%32 574